ESR1基因多态性对骨质疏松症结局的差异性遗传影响
John P A Ioannidis1, Stuart H Ralston, Simon T Bennett
1Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. jioannid@cc.uoi.gr
JAMA
|November 4, 2004
概括
雌激素受体α (ESR1) 基因影响骨折风险,而不是骨密度. 一种特定的ESR1变体XbaI通过独立于骨矿物密度的机制显著降低女性骨折风险.
科学领域:
- 遗传学和骨细胞生物学
- 骨质疏松症研究 骨质疏松症研究
- 分子内分泌学分子内分泌学
背景情况:
- 骨矿物质密度 (BMD) 和骨折风险受到遗传因素的重大影响.
- 雌激素受体α (ESR1) 是骨质疏松症的关键候选基因,但之前对其多形态的研究由于样本小等局限性而产生了不确定的结果.
研究的目的:
- 调查常见的ESR1基因多态 (XbaI,PvuII,TA重复) 及其类型与骨损伤和骨折风险之间的关联.
- 通过分析个人级别数据来产生大规模可靠的证据.
主要方法:
- 对来自8个欧洲中心的18917名参与者的个人数据进行了元分析.
- 标准化基因型鉴定用于ESR1多态性 (XbaI [rs9340799],PvuII [rs2234693],和促进体TA重复).
- 骨矿物质密度 (大腿部,腰椎) 和骨折数据 (所有骨折,脊椎骨折) 根据基因型进行了分析.
主要成果:
- 研究ESR1多态或单元型与骨矿物质密度之间没有发现显著的关联.
- 在没有XbaI识别部位的女性中,观察到骨折风险显著降低:所有骨折减少19%,脊椎骨折减少35%.
- 这些骨折风险降低独立于骨质量,在调整后仍然显著.
结论:
- ESR1基因在骨折易受性中起作用.
- 在ESR1中的XbaI多态性影响骨折风险通过不同的途径与其对BMD的影响.
- 这项研究强调了大型标准化研究对于准确评估常见遗传变异对骨质疏松症等复杂疾病的影响的重要性.
更多相关视频
相关概念视频
Multiple Allele Traits
The Concept of Multiple Allelism
Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
RNA Splicing
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


